{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T16:26:34Z","timestamp":1787415994527,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018708","name":"Euratom Research and Training Programme","doi-asserted-by":"publisher","award":["900009"],"award-info":[{"award-number":["900009"]}],"id":[{"id":"10.13039\/100018708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018708","name":"Euratom Research and Training Programme","doi-asserted-by":"publisher","award":["PI24\/00982"],"award-info":[{"award-number":["PI24\/00982"]}],"id":[{"id":"10.13039\/100018708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018708","name":"Euratom Research and Training Programme","doi-asserted-by":"publisher","award":["PI21\/01653"],"award-info":[{"award-number":["PI21\/01653"]}],"id":[{"id":"10.13039\/100018708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","award":["JR20\/00019"],"award-info":[{"award-number":["JR20\/00019"]}],"id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejca.2026.116955","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:08:44Z","timestamp":1784732924000},"page":"116955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials"],"prefix":"10.1016","volume":"245","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7039-4840","authenticated-orcid":false,"given":"Edouard","family":"Auclin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Roulleaux Dugage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Gorr\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Laguna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1062-1436","authenticated-orcid":false,"given":"Diana","family":"Anguita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2026-4076","authenticated-orcid":false,"given":"Angela","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5691-441X","authenticated-orcid":false,"given":"Michele","family":"Rota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7806-2979","authenticated-orcid":false,"given":"Miquel","family":"Ferriol-Galmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-2722","authenticated-orcid":false,"given":"Charles","family":"Vauchier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernelle","family":"Lavaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mezquita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejca.2026.116955_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2026.116955_bib2","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"10212","key":"10.1016\/j.ejca.2026.116955_bib3","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"23","key":"10.1016\/j.ejca.2026.116955_bib4","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116955_bib5","article-title":"Clinical characteristics and management of long survivors in extensive stage small cell lung cancer","volume":"202","author":"Gobbini","year":"2025","journal-title":"Lung Cancer Amst Neth"},{"issue":"3","key":"10.1016\/j.ejca.2026.116955_bib6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ejca.2026.116955_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12943-024-02014-x","article-title":"Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study","volume":"23","author":"Xie","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ejca.2026.116955_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116955_bib9","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3390\/cancers15041066","article-title":"Prognostic value of the lung immune prognosis index score for patients treated with immune checkpoint inhibitors for advanced or metastatic urinary tract carcinoma","volume":"15","author":"Parent","year":"2023","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.ejca.2026.116955_bib10","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.3390\/cancers13153776","article-title":"Association of the lung immune prognostic index with immunotherapy outcomes in mismatch repair deficient tumors","volume":"13","author":"Auclin","year":"2021","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.ejca.2026.116955_bib11","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.3390\/cancers16234053","article-title":"Association of Lung Immune Prognostic Index (LIPI) with disease control rate and progression-free survival in patients with soft-tissue sarcoma treated with immunotherapy in early-phase trials","volume":"16","author":"Zoghbi","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2026.116955_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1747","article-title":"Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer","author":"Kazandjian","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116955_bib13","article-title":"Validation of the lung immune prognostic index in patients with untreated advanced non-small cell lung cancer: post hoc analysis of the IMpower 130, 131 and 150 trials","volume":"199","author":"Auclin","year":"2025","journal-title":"Lung Cancer Amst Neth"},{"issue":"10","key":"10.1016\/j.ejca.2026.116955_bib14","doi-asserted-by":"crossref","first-page":"S973","DOI":"10.1016\/j.jtho.2018.08.1834","article-title":"P3.12-11 Association of the lung immune prognostic index (LIPI) with outcomes for immune checkpoint inhibitors in diffuse SCLC patients","volume":"13","author":"Mezquita","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2026.116955_bib15","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s11912-022-01335-8","article-title":"Biological rationale for peripheral blood cell-derived inflammatory indices and related prognostic scores in patients with advanced non-small-cell lung cancer","volume":"24","author":"Banna","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"25","key":"10.1016\/j.ejca.2026.116955_bib16","first-page":"00285","article-title":"Small-cell lung cancer: anatomy of an immune-cold tumor","volume":"S2405-8033","author":"Millrine","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejca.2026.116955_bib17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semcancer.2022.11.007","article-title":"Role of LDH in tumor glycolysis: regulation of LDHA by small molecules for cancer therapeutics","volume":"87","author":"Sharma","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116955_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.trecan.2024.01.010","article-title":"Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC","volume":"10","author":"Horvath","year":"2024","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116955_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41423-024-01244-9","article-title":"Neutrophils in cancer: from biology to therapy","volume":"22","author":"Koenderman","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.ejca.2026.116955_bib20","first-page":"211","article-title":"Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics","volume":"151","author":"Mezquita","year":"2021","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"5","key":"10.1016\/j.ejca.2026.116955_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/curroncol32050261","article-title":"ADCs and TCE in SCLC therapy: the beginning of a new era?","volume":"32","author":"Muscolino","year":"2025","journal-title":"Curr Oncol Tor Ont"},{"issue":"21","key":"10.1016\/j.ejca.2026.116955_bib22","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ejca.2026.116955_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ejca.2026.116955_bib24","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1080\/14796694.2025.2565995","article-title":"IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer","volume":"21","author":"Owonikoko","year":"2025","journal-title":"Future Oncol Lond Engl"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T16:19:45Z","timestamp":1787415585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"alternative-id":["S0959804926007367"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116955","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116955"}}